Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05415345
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:36.916399+00:00
Published At
2022-06-13T00:00:00+00:00
Record Updated At
2022-06-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Human Papilloma Virus Infection Type 16", "Human Papilloma Virus Infection Type 18", "Hepatitis E Virus Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-06-13"
protocolSection.identificationModule.nctId
"NCT05415345"
protocolSection.identificationModule.officialTitle
"Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Human Papilloma Virus Infection Type 16 (protocolSection.conditionsModule.conditions)
  • Human Papilloma Virus Infection Type 18 (protocolSection.conditionsModule.conditions)
  • Hepatitis E Virus Infection (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.